Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report

AYGEN B., DEMİR A. M., Gumus M., Karabay O., KAYMAKOĞLU S., Koksal A. S., ...More

TURKISH JOURNAL OF GASTROENTEROLOGY, vol.29, no.3, pp.259-269, 2018 (SCI-Expanded) identifier

  • Publication Type: Article / Review
  • Volume: 29 Issue: 3
  • Publication Date: 2018
  • Doi Number: 10.5152/tjg.2018.18263
  • Journal Name: TURKISH JOURNAL OF GASTROENTEROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.259-269
  • Keywords: Hepatitis B, immunosuppressive therapy, reactivation risk, antiviral prophylaxis, STEM-CELL TRANSPLANTATION, VIRUS HBV REACTIVATION, CYTOTOXIC CHEMOTHERAPY, SURFACE-ANTIGEN, CANCER-PATIENTS, PREVENTION, MANAGEMENT, LYMPHOMA, IDENTIFICATION, PROPHYLAXIS
  • Acibadem Mehmet Ali Aydinlar University Affiliated: No

Abstract

This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, prophylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to the risk of hepatitis B reactivation emergency. To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions.